COMMUNIQUÉS West-GlobeNewswire

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
10/08/2026
Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimab The primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab’s 60 mg with induction, and [...]
Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates
10/08/2026
AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive 16-week Phase 2 [...]
Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
10/08/2026
Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin ® -C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients [...]
Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF
10/08/2026
TNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placebo In prespecified exploratory analyses in the overall trial population, treatment with TNX-103 [...]
Curium acquires Abscint SA, expanding PET radiodiagnostic pipeline in oncology
10/08/2026
Acquisition adds ABS-011, an investigational Phase 2b gallium-68-labeled PET radiodiagnostic tracer targeting HER2 Transaction strengthens Curium radiodiagnostic capabilities and oncology footprint, including in breast [...]
Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
10/08/2026
EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026 EVERLAST-B fully enrolled ahead of schedule, with Week 16 data now expected in 4Q 2026 Phase 3 program [...]
Kraig Biocraft Laboratories CEO Kim Thompson Publishes Thought Leadership Article on the Next Chapter of Authored Biology in Biocompare
10/08/2026
Byline Article Introduces "Authored Biology" Framework and Draws on Kraig Labs' Spider Silk Journey to Chart the Future of Biology-Enabled Manufacturing ANN ARBOR, Mich., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft [...]
Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint
10/08/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 10 AUGUST 2026 at 14.05 EEST Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart [...]
Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board
10/08/2026
Experienced Merck researcher will expand the Board’s drug discovery expertise MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical [...]
Surgery Partners, Inc. Announces Second Quarter 2026 Results Reaffirms Full Year 2026 Guidance
10/08/2026
Reaffirms Full Year 2026 Guidance BRENTWOOD, Tenn., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator [...]
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
10/08/2026
Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation under the United Kingdom’s Innovative [...]
Glass House Brands to Host Second Quarter 2026 Earnings Call on August 13, 2026
10/08/2026
LONG BEACH, Calif. and TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (NYSE: GLAS) today announced that it will report financial results for the [...]
Alvotech to Report Financial Results for H1 2026
10/08/2026
REYKJAVIK, Iceland, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for [...]
Novo Nordisk and AWS enter strategic partnership to accelerate drug discovery through AI
10/08/2026
New AI co-innovation hub in London brings together AWS engineers, AI specialists, and applied scientists alongside Novo Nordisk research and development teams to increase productivity and help reduce the time to market [...]
Clene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated Approval
10/08/2026
Survival benefit is concentrated in participants with NfL biomarker response: CNM-Au8 ® -treated patients whose NfL declined or stabilized lived significantly longer than concurrently randomized controls Functional [...]
Park Dental Partners, Inc. Announces Agreement to Acquire Village Family Dental Services Organization - Enters North Carolina Market
10/08/2026
The transaction is expected to add 12 practice locations and 48 doctors in North Carolina MINNEAPOLIS, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK). (the “Company”), a leading dental [...]
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
10/08/2026
On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Application submitted to FDA on June 30 Completed [...]
Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
10/08/2026
SPY772 program aims to deliver best-in-indication efficacy and convenience in Hidradenitis Suppurativa through dual inhibition of TL1A and IL-17A/F in a long-acting coformulation Phase 2 SKYLIGHT trial designed to [...]
Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader
10/08/2026
Establishes an integrated global platform spanning biosimilar R&D, manufacturing and commercialization Adds a major long-term growth pillar and extends Amneal’s growth profile into the 2030s BRIDGEWATER, N.J., Aug. [...]

Pages